Flt3 binding proteins and methods of use
AssigneeHarpoon Therapeutics, Inc.
InventorsHolger WESCHE, Richard J. AUSTIN
Life of this patent
Estimating the term…
Abstract
Provided herein are FLT3 binding proteins, pharmaceutical compositions comprising such proteins or fragments thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such FLT3 binding proteins. Also disclosed are methods of using the disclosed FLT3 binding proteins in the prevention, and/or treatment of diseases, conditions and disorders.
Claims30
An FLT3 binding domain comprising at least three complementarity determining regions (a CDR1, a CDR2, and a CDR3), wherein
- the CDR1 comprises a sequence selected from the group consisting of SEQ ID Nos. 89, 91, and 100, or a sequence comprising one or more amino acid substitutions in a sequence selected from the group consisting of SEQ ID Nos. 89, 91, and 100;
- the CDR2 comprises a sequence selected from the group consisting of SEQ ID Nos. 149, 151, 393, and 394, or a sequence comprising one or more amino acid substitutions in a sequence selected from the group consisting of SEQ ID Nos. 149, 151, 393, and 394;
- the CDR3 comprises a sequence selected from the group consisting of SEQ ID Nos. 173, 186, and 195, or a sequence comprising one or more amino acid substitutions in a sequence selected from the group consisting of SEQ ID Nos. 173, 186, and 195.
An FLT3 targeting trispecific protein comprising
- (A) a first domain that binds a human CD3;
- (B) a second domain that binds a human serum albumin protein;
- and
- (C) a third domain that binds a human FLT3,
- wherein the CDR1 comprises a sequence selected from the group consisting of SEQ ID Nos. 89, 91, and 100, or a sequence comprising one or more amino acid substitutions in a sequence selected from the group consisting of SEQ ID Nos. 89, 91, and 100;
- the CDR2 comprises a sequence selected from the group consisting of SEQ ID Nos. 149, 151, 393, and 394, or a sequence comprising one or more amino acid substitutions in a sequence selected from the group consisting of SEQ ID Nos. 149, 151, 393, and 394;
- and the CDR3 comprises a sequence selected from the group consisting of SEQ ID Nos. 173, 186, and 195, or a sequence comprising one or more amino acid substitutions in a sequence selected from the group consisting of SEQ ID Nos. 173, 186, and 195.
A method of treating a hematologic malignancy, the method comprising administering to a subject in need thereof a FLT3 targeting trispecific protein comprising
- (A) a first domain that binds a human CD3;
- (B) a second domain that binds a human serum albumin protein;
- and
- (C) a third domain that binds a human FLT3,
- wherein the CDR1 comprises a sequence selected from the group consisting of SEQ ID Nos. 89, 91, and 100, or a sequence comprising one or more amino acid substitutions in a sequence selected from the group consisting of SEQ ID Nos. 89, 91, and 100;
- the CDR2 comprises a sequence selected from the group consisting of SEQ ID Nos. 149, 151, 393, and 394, or a sequence comprising one or more amino acid substitutions in a sequence selected from the group consisting of SEQ ID Nos. 149, 151, 393, and 394;
- the CDR3 comprises a sequence selected from the group consisting of SEQ ID Nos. 173, 186, and 195, or a sequence comprising one or more amino acid substitutions in a sequence selected from the group consisting of SEQ ID Nos. 173, 186, and 195.
Dependencies are inferred from the claim text.